Overall rank by patents
#29,026
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
ID Pharma Co., Ltd.
USPTO PatentsView assignee record - 9 granted patents across 4 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
9
Total patents granted
4
CPC technology areas
8.4
Avg claims per patent
+100%
5-year filing velocity
The verdict
ID holds 9 US patents across 4 technology areas, rank #29,026 of 50,000 tracked assignees.
- #29,026
- of 50,000 US assignees by volume
- Top 93%
- by Innovation Score (20.1/100)
- 8.4
- avg claims per patent
- +100%
- filing velocity, last 5 yrs
Portfolio overview
ID Pharma Co., Ltd. has been granted 9 US utility patents between 2016 and 2025, placing ID Pharma Co., Ltd. at rank #29,026 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 8.4 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a Foreign Corporation, ID Pharma Co., Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, ID sits between Icare Finland OY (9 patents, rank #29,022) and IGM Resins Italia S.r.l. (9 patents, rank #29,030) - the closest US assignees by grant volume. The composite Innovation Score of 20.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 3 in the 2015–2019 window, a +100% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. ID Pharma Co., Ltd.'s 8.4 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark ID Pharma Co., Ltd. against peers pursuing similar technology classes.
Who files at ID's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Icare Finland OY
ICARE FINLAND OY
9 patents
- ICG Licensing
ICG Licensing LLC
9 patents
- ICON Bioscience
ICON BIOSCIENCE, INC.
9 patents
- ICOS
ICOS CORPORATION
9 patents
- IDM Global
IDM GLOBAL, INC.
9 patents
- IDSC Holdings
IDSC Holdings LLC
9 patents
- IFCO Systems
IFCO SYSTEMS GMBH
9 patents
- IGM Resins Italia…
IGM RESINS ITALIA S.R.L.
9 patents
- ID Pharma ◀
ID Pharma Co., Ltd.
9 patents
What this shows ID holds 9 patents at rank #29,026, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near ID
By rank, the assignees closest to #29,026 in granted patent volume.
- Icare Finland OY #29,022 · 9 patents
- ICG Licensing Llc #29,023 · 9 patents
- ICON Bioscience, Inc. #29,024 · 9 patents
- ICOS Corporation #29,025 · 9 patents
- IDM Global, Inc. #29,027 · 9 patents
- IDSC Holdings Llc #29,028 · 9 patents
- IFCO Systems Gmbh #29,029 · 9 patents
- IGM Resins Italia S.r.l. #29,030 · 9 patents
Leaders in C12N (Microorganisms OR Enzymes)
Other assignees with the most granted patents in ID's primary technology class.
- Monsanto Technology Llc 1,335 in class
- The Regents Of The University Of California 1,161 in class
- Novozymes A/s 656 in class
- Immatics Biotechnologies Gmbh 647 in class
- Pioneer Hi-bred International, Inc. 623 in class
- President And Fellows Of Harvard College 594 in class
- Massachusetts Institute Of Technology 541 in class
- The Trustees Of The University Of Pennsylvania 537 in class
ID's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
20 Top 93% higher than 7% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 11.1% |
| 2017 | 1 | 11.1% |
| 2018 | 1 | 11.1% |
| 2020 | 2 | 22.2% |
| 2021 | 3 | 33.3% |
| 2025 | 1 | 11.1% |
Which technologies does ID Pharma Co., Ltd. patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Simple
Velocity Accelerating
Frequently Asked Questions
How many patents does ID Pharma Co., Ltd. hold?
ID Pharma Co., Ltd. holds 9 US granted patents filed between 2016 and 2025, spanning 4 technology areas.
What is ID Pharma Co., Ltd.'s Innovation Score?
ID Pharma Co., Ltd. has an Innovation Score of 20.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does ID Pharma Co., Ltd. focus on?
ID Pharma Co., Ltd.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 9 patents. The company has filed patents in 4 CPC subclasses total.
Is ID Pharma Co., Ltd.'s patent filing rate increasing or decreasing?
ID Pharma Co., Ltd.'s recent filing velocity is +100% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for ID Pharma Co., Ltd.'s patents?
ID Pharma Co., Ltd.'s patents average 8.4 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the ID Pharma Co., Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
ID's 9 grants land it in the top 93% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - ID ranks #29,026 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.